694471-97-1Relevant articles and documents
COMPOUNDS WITH PGD2 ANTAGONIST ACTIVITY
-
Page/Page column 63, (2010/02/11)
Compounds of general formula (I); wherein R1, R2, R3 and R4 are independently hydrogen, halo, -C1-C6 alkyl, -O(C1-C6 alkyl), -C1-C6 alkyl(C3-C7 cycloalkyl), -CON(R9)2, -SOR9, -S02R9, -S02N(R9)2, -N(R9)2, -NR9OR9, -C02R9, COR9, -SR9, -OH, -N02 or -CN; each R9 independently hydrogen or C1-C6 alkyl, R5 and R6 are each independently hydrogen, or C1-C6 alkyl or together with the carbon atom to which they are attached form a C3-C7 cycloalkyl group; R7 is hydrogen or C1-C6 alkyl; R8 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or an aromatic moiety, any of which may optionally be substituted with one or more substituents selected from halo, -SOR13 -S02R13, -R14, -OR14, -CON(R14)2 -SOR14, -S02R14, -S02N(R14) -S02N(R14)2, -N(R 14)2, NR14COR14, -CO2R14, COR14, -SR14, -N02 or -CN; wherein R13 is a 5 to 7 membered heterocyclic ring, and each R14 is independently hydrogen, alkyl or aryl, the aryl being optionally substituted by -R9, -OR9, -CON(R9)2, -SOR9 -S02R9, -S02N(R9)2, -N(R9)2, NR9COR9, -C02R9, -COR9, -SR9, halo, -N02 or -CN, wherein R9 is as defined above; provided that when R1, R3 and R4 are hydrogen and R2 is hydrogen, halogen or -0(C1-C6)alkyl, R8 is not unsubstituted phenyl or phenyl substituted by halo, C1-C6 alkyl, -0(C1-C6)alkyl, -S(C1-C6)alkyl or -CO(C1-C6)alkyl, or pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs therof are useful in the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis
PPAR ACTIVE COMPOUNDS
-
Page 166-168, (2008/06/13)
Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.